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Abstract: Treatment with several antipsychotic drugs exhibits a tendency to induce weight gain
and diabetic complications. The proposed mechanisms by which the atypical antipsychotic drug
olanzapine increases body weight include central dysregulations leading to hyperphagia and
direct peripheral impairment of fat cell lipolysis. Several investigations have reproduced in vitro
direct actions of antipsychotics on rodent adipocytes, cultured preadipocytes, or human adipose
tissue-derived stem cells. However, to our knowledge, no such direct action has been described
in human mature adipocytes. The aim of the present study was to compare in human adipocytes
the putative direct alterations of lipolysis by antipsychotics (haloperidol, olanzapine, ziprazidone,
risperidone), antidepressants (pargyline, phenelzine), or anxiolytics (opipramol). Lipolytic responses
to the tested drugs, and to recognized lipolytic (e.g., isoprenaline) or antilipolytic agents (e.g.,
insulin) were determined, together with glucose transport and amine oxidase activities in abdominal
subcutaneous adipocytes from individuals undergoing plastic surgery. None of the tested drugs
were lipolytic. Surprisingly, only opipramol exhibited substantial antilipolytic properties in the
micromolar to millimolar range. An opipramol antilipolytic effect was evident against isoprenaline-,
forskolin-, or atrial natriuretic peptide-stimulated lipolysis. Opipramol did not impair insulin
activation of glucose transport but inhibited monoamine oxidase (MAO) activity to the same extent
as antidepressants recognized as MAO inhibitors (pargyline, harmine, or phenelzine), whereas
antipsychotics were inefficient. Considering its unique properties, opipramol, which is not associated
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with weight gain in treated patients, is a good candidate for drug repurposing because it limits
exaggerated lipolysis, prevents hydrogen peroxide release by amine oxidases in adipocytes, and is
thereby of potential use to limit lipotoxicity and oxidative stress, two deleterious complications of
diabetes and obesity.
Keywords: adipose tissue; obesity; monoamine oxidase; semicarbazide-sensitive amine oxidase;
glucose transport; lipotoxicity; insulin; antidepressant; antipsychotic; harmine; phenelzine; opipramol
1. Introduction
Many of the pharmaceutical agents prescribed to treat neuropsychiatric disorders exert metabolic
effects. Several antipsychotic drugs, especially those associated with weight gain in treated
schizophrenic patients [1], have been evidenced to enhance lipid storage in adipocytes [2]. However, it
remains poorly determined whether extra-neuronal effects on adipocytes contribute to the unwanted
fattening occurring during treatment, and even a few studies have reported that, at therapeutic
concentrations, various antipsychotic agents cannot directly influence adipocyte metabolism [3]. The
weight gain could therefore be a side-effect mainly triggered by central disturbances, such as increased
food intake, leading to excessive calorie intake, then fattening, than by a direct activation of lipid
storage [4,5]. In addition, it remains unclear whether it is the pharmaceutical treatment or the health
recovery of the treated patient that influences food consumption. Nevertheless, numerous reports
have indicated that various psychoactive agents are capable of directly modulate lipid accumulation
in fat cells during short-term in vitro experiments. This is the case, but in the opposite sense, for an
antidepressant drug, phenelzine, which inhibits insulin-induced lipogenesis in fat cells in less than an
hour [6], impairs adipogenesis in cultured cells in the range of several days [7], and limits fat deposition
in rodents chronically treated for weeks [8,9]. Indeed, the demonstration of a direct effect of a given
psychoactive drug on adipocytes does not prevent the molecule to act in a concerted manner on gene
regulation, and elsewhere on other cell types (and vice versa).
Due to these considerations stated, it appears of utmost importance to further explore whether
adipose tissue is a site of action of antipsychotic drugs, especially those triggering metabolic
dysregulation (e.g., olanzapine). In fact, the accumulation/breakdown of triglycerides in the lipid
droplet of fat cells is rapidly regulated by neuronal, endocrine, and paracrine inputs, and is sensitive to
many pharmacological agents. Previous investigations have been performed by measuring adipocyte
biological functions and determining the regulations of key genes involved in metabolic pathways,
either in adipocytes from treated animal models [10], or after short- or long-term incubation of
cultured adipose cells with psychoactive molecules. To briefly mention examples of such different
approaches, it is worth mentioning that the decreased lipolytic effect of isoprenaline and down-regulated
hormone-sensitive lipase gene (Hsl) were found in adipocytes from olanzapine-treated rats [10], whereas
increased lipid accumulation and adipogenic gene upregulation were observed in cultured adipocytes
treated with olanzapine [2,11–14]. In this view, the reduction of the rates of lipolysis in response
to the β-adrenergic agonist isoprenaline was consistently reported in both rats [10] and cultured
preadipocytes [14] treated with olanzapine. Moreover, atypical antipsychotics have been described to
alter other biological functions of adipocytes, not only related with the management of triglyceride
storage/breakdown (lipogenesis and lipolysis) [11,15], but also related to insulin sensitivity and
inflammation, such as adipokine secretion [12,14], therefore favoring the onset of insulin resistance.
Nevertheless, no functional studies of the lipolytic responses to neuropsychiatric drugs have been
performed in human mature adipocytes to date, whereas it has been documented that several
antipsychotic drugs alter in vitro gene expression in human mesenchymal stem cells differentiated
into adipocytes [2,16–18]. Besides focusing interest on lipolysis regulation, exploring the functional
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responses of freshly isolated human fat cells gives a greater preclinical interest to the reported
pharmaceutical properties than observations performed on animal models or cell cultures.
Thus, in an attempt to obtain further insights on the direct effects of antipsychotic drugs on
triglyceride breakdown in human adipocytes, we included olanzapine in the present comparative
study for the evident following reasons. Olanzapine is a second-generation antipsychotic drug
recognized for its metabolic side-effects in humans, leading to overweight and diabetes [4]. Rodents
have provided valuable information about the olanzapine-induced metabolic adverse events, and a
gender preferential overweight has been reported in female rats [10,19]. Olanzapine actions encompass
mid-term regulations of gene expression [18], adipose tissue hypertrophy during prolonged treatment in
rats [10,19], and even multigenerational alteration of glucose homeostasis in mice [20]. However, to our
knowledge, only scarce information is available regarding olanzapine action on human adipocytes [17].
Other atypical antipsychotics such as ziprazidone or risperidone, claimed to develop less
deleterious side-effects, were included in our comparative approach, especially when considering that
fat stores can accumulate such lipophilic antipsychotic drugs up to 30 times higher than their therapeutic
plasma levels [21]. Haloperidol was also tested as a reference of first-generation antipsychotics,
exhibiting less “obesogenic” actions. We also included in this study several other psychoactive agents
such as the antidepressant and neuroprotective agent phenelzine [22] in view of its above-mentioned
inhibitory effects on lipid deposition.
Opipramol was prescribed for the treatment of anxious depression in the 1960s; it is a tricyclic
antidepressant that does not inhibit the neuronal uptake of norepinephrine and/or serotonin [23].
Instead, it is considered as a weak dopaminergic, histaminergic, and serotoninergic antagonist,
and binds to sigma receptors in the brain [23]. Our tests on mature adipocytes were therefore also
extended to opipramol, as it is a psychotropic drug belonging to the classes of antidepressants,
antipsychotics, and anxiolytics, but is not clearly associated with adverse effects affecting body
weight regulation.
Our aim was to explore the short-term effects of the antipsychotics influencing body weight,
as well as related anxiolytic, antiepileptic, or antidepressant drugs, on functional responses of
human fat cells. Alongside the test of their lipolytic and antilipolytic capacities on freshly isolated
adipocytes, we also studied their putative interactions with the amine oxidases expressed in adipocytes.
Exploring the effects on monoamine oxidase (MAO) was driven by the similarities between the
adipose (mainly of the A form in human adipocytes [24]) and the brain forms, well known to be
the target of a class of antidepressants, the MAO inhibitors, which have been recently reported to
mitigate excessive fat deposition in rodents [8,9,25,26]. Thus, pargyline, phenelzine, and harmine were
used as representatives of MAO inhibitors in both assays of lipolytic or amine oxidation activities.
Our approach also encompassed the study of putative interplay with the semicarbazide-sensitive amine
oxidase (SSAO), highly expressed in human adipocytes [27], as several SSAO inhibitors (semicarbazide,
phenelzine) are also endowed with potential anti-obesity properties [28]. Finally, for several of the
above-mentioned pharmaceutical agents, our investigations compared their effects on hydrogen
peroxide release by adipose tissue and on glucose transport because we have previously reported that
amine oxidase substrates stimulate adipogenesis in cultured preadipocytes and glucose transport in
adipocytes in a hydrogen peroxide-dependent manner [27].
The following results will indicate that, unexpectedly, opipramol behaved differently from the
other psychoactive drugs in human adipose tissue by exhibiting substantial antilipolytic properties
without altering glucose uptake capacities of human fat cells, and by exerting MAO inhibition.
2. Materials and Methods
2.1. Materials
Opipramol (4-[3-(5H-dibenz[b,f]-azepine-5-yl)-propyl]-1-piperazine-ethanol dihydrochloride),
haloperidol, risperidone, phenelzine, pargyline, harmine, tyramine, benzylamine, semicarbazide,
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cytochalasin B, fatty acid-free bovine serum albumin, hydrogen peroxide, horseradish peroxidase,
isoprenaline, cytochalasin B, and routinely used chemicals were obtained from Sigma-Aldrich-Merck
(St. Quentin Fallavier, France), unless otherwise specified. Amplex Red was provided by InterChim
(Montluçon, France). [3H]-2-Deoxyglucose, [14C]-benzylamine, and scintillation cocktail were
purchased from PerkinElmer (Boston, MA, USA). Different [14C]-tyramine batches were either from
PerkinElmer or Sigma. Olanzapine and ziprazidone were generous gifts from Prof. Renaud de
Beaurepaire (Hosp. Paul-Guiraud, Villejuif, France).
2.2. Subjects and Preparation of Adipose Cells
Samples of human subcutaneous adipose tissue (hScAT) were obtained from patients undergoing
abdominal lipectomy at the plastic surgical department of the Rangueil Hospital (CHU Toulouse,
France) in accordance with the local ethic committee and French National Institute of Health (INSERM)
guidelines under the agreement reference DC-2008-452. The adipocyte preparations used in the present
study were obtained from a total of 26 healthy individuals (24 women) of a mean age of 39 years
with a mean body mass index of 25.1 ± 0.8 kg/m2. As freezing/thawing sequences do not apply for
obtaining functional adipocytes, the fat cells were immediately isolated by collagenase digestion as
previously described [27]. Once cut into small pieces with scissors, portions of adipose tissue samples
were digested at 37 ◦C under agitation. Meanwhile remaining portion of the samples was immediately
frozen free from buffer at −80 ◦C in 35 mL plastic vials for subsequent homogenate preparation and
determination of amine oxidase activities. Filtration of the digested pieces through nylon stockings
and two washes of the buoyant fat cells allowed us to obtain preparations of functional adipocytes in
Krebs-Ringer buffer with 15 mM bicarbonate, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid and 3.5% of bovine serum albumin (pH 7.4). A total of 6 mM glucose was added to this medium
for lipolysis assays, but omitted for glucose uptake assays, performed with only the non metabolisable
analog 2-deoxy-glucose as already reported [29].
2.3. Lipolysis Assays
Adipocyte suspension was distributed in plastic vials containing 400 µL and incubated at 37 ◦C
under shaking (150 cycles/min) in the absence (basal) or in the presence of the indicated agents.
After 90 min, the incubation tubes were placed on ice and 150 µL of cell medium was removed for
the enzymatic determination of glycerol, as described previously [29]. Results were expressed as
micromoles of glycerol released per 100 mg cell lipid for 90 min, as in [30]. As glycerol is an end-product
of lipolysis less re-used than free fatty acids by human adipocytes, its release served as an index of
lipolytic activity throughout the study, as in [31].
2.4. Oxidation of Radiolabeled Tyramine and Benzylamine by Adipose Tissue Homogenates
Human adipose tissue samples were thawed and homogenized at room temperature in 200 mM
phosphate buffer (pH 7.5 for 30 s) to avoid the formation of a fat cake that is solid at cold temperatures
and hampers enzymatic reactions. Amine oxidase activities were measured at room temperature with
[14C]- tyramine or [14C]-benzylamine in 200 mM phosphate buffer, pH 7.5, for 30 min, as previously
described [30]. The tested agents were preincubated for 15 min with homogenates prior the addition
of substrate, which launched the reaction for 30 min, as in [32].
2.5. Hydrogen Peroxide Production by Adipose Tissue Homogenates
Activity of human amine oxidase was assessed by determining the hydrogen peroxide released
by amine oxidation in homogenates of thawed hScAT. The same fluorimetric method was applied for
MAO and for SSAO activity assays [33]. Hydrogen peroxide release was detected with a chromogenic
mixture (4 U/mL horseradish peroxidase, 40 µM of fluorescent probe Amplex Red) in phosphate buffer,
pH 7.5, and quantified with hydrogen peroxide standard curve (from 0.05 to 5 µM concentrations).
Homogenates were distributed in 96-well dark microplates and incubated at 37 ◦C (200 µL/well) after
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pre-incubation without (control) or with the tested agents or 1 mM semicarbazide to abolish SSAO,
or 1 mM pargyline to block MAO activity. Fluorescence data (ex/em: 540/590 nm) were collected on a
Fluoroskan Ascent microplate reader (ThermoLabsystems, Finland), as in [34].
2.6. Glucose Transport Assays
After preincubation for 45 min at 37 ◦C with insulin, and/or indicated drugs, each vial (400 µL)
received an isotopic dilution of the non-metabolizable hexose 2-deoxy-D-[3H]glucose, giving a final
concentration of 0.1 mM (devoid of cold glucose, and equivalent to approximately 1,000,000 dpm per
vial). Assays were then incubated for a 10 min period and stopped with 100 µL of 100 µM cytochalasin
B. The radioactivity incorporated into the fat cells was separated by adding dinonyl phthalate (density
0.98 g/mL) and a pulse spin to microtubes containing 200 µL aliquots of cell suspension, as previously
reported [29]. The upper part of the tubes, containing buoying adipocytes, were cut and counted in
scintillation vials, as previously described [35].
2.7. Data Presentation and Statistical analyses
Experimental data are given as mean ± standard error of the mean (SEM) of the indicated
number of independent observations, presented as histograms generated with Microsoft Excel and
Powerpoint 14.6 for Mac or curves processed with GraphPad Prism 8.0, were analyzed by one-way
ANOVA or Student’s t-test when appropriate. Statistical significance was assumed when p < 0.05; NS:
not significantly different.
3. Results and Discussion
3.1. In Vitro Evaluation of the Direct Influence of Antipsychotics on the Lipolytic Responses of Human Adipose
Cells
The lipolytic response of adipocytes freshly isolated from human subcutaneous fat depots
represents a relatively simple model of assessing whether antipsychotic or antidepressant drugs
can produce extra-neuronal effects, and thereby may alter body weight regulation or insulin
sensitivity, besides altering satiety signals. Adipocyte lipolysis consists in an intracellular triglyceride
breakdown leading to the release of glycerol and free fatty acids in the surrounding medium.
Such biological function is finely regulated by lipolytic and antilipolytic modulators. Among the
former, isoprenaline is a β-adrenergic agonist of reference (also known as isoproterenol), widely used
for in vitro studies because it is capable of activating lipolysis to similar levels compared with the
natural catecholamines epinephrine and norepinephrine, which activate both the lipolytic β- and
antilipolytic α2-adrenoreceptors. Alongside isoprenaline, two other well-recognized lipolytic agents
have been included in our study: forskolin, a direct activator of adenylyl-cyclase, and atrial natriuretic
peptide (ANP), which activates guanylyl-cyclase in human adipocytes [36]. Insulin, the physiological
antilipolytic hormone, was used as well as tyramine, a substrate of amine oxidases, for which we
recently reported that its capacity to inhibit lipolysis is dependent on hydrogen peroxide production
by human fat cells [31].
The influence of several antipsychotic agents was first tested on human adipocyte lipolysis
under basal and isoprenaline-stimulated conditions. Basal lipolysis was not modified by haloperidol,
representative of the first-generation antipsychotics, or by olanzapine, ziprasidone, and risperidone,
which belong to the second-generation antipsychotics, at least when the drugs were incubated at 0.1
to 100 µM during 90 min with the adipocytes. All the drugs were unable to modify the basal value,
which was 0.21 ± 0.03 µmoles of glycerol released per 100 mg cell lipid per 90 min, as they reached at
100 µM of the respective levels: haloperidol 0.26 ± 0.04, olanzapine 0.27 ± 0.04, ziprazidone 0.23 ± 0.03,
and risperidone 0.22 ± 0.04 µmol/100 mg/90 min (n = 10–11; NS).
In contrast, isoprenaline clearly stimulated lipolysis in a dose-dependent manner, and this
was not altered by the presence of 100 µM of the above-mentioned antipsychotics (Figure 1). No
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significant differences were observed between the respective EC50 values obtained from non-linear
regression analysis of the dose response-curves: isoprenaline: 2.5 ± 0.5 nM; isoprenaline + ziprazidone:
4.6 ± 3.1 nM; isoprenaline + olanzapine: 4.6 ± 11.8 nM; isoprenaline + haloperidol: 4.7 ± 3.4 nM;
isoprenaline + risperidone: 10.7 ± 13.4 nM. The only observed direct effect of these antipsychotics was
that of risperidone, which impaired the submaximal effect of 10 nM isoprenaline without altering its
maximal lipolytic effect (Figure 1).
Figure 1. Dose–response curves for isoprenaline stimulation of lipolysis in human subcutaneous
adipocytes in the presence of antipsychotic drugs. Each point is the mean± SEM of 10–11 determinations,
performed in control conditions with isoprenaline alone (iso alone, black circles) or in combination
with 100 µM of the indicated drugs. A significant difference from the corresponding control lipolytic
response was found only in the presence of risperidone (iso+risperidone, blue circles), at: * p < 0.05.
These observations contrast with the reported rapid inhibition of basal lipolysis by ziprazidone
in rat fat cells, but they confirm the lack of immediate action of haloperidol and olanzapine [10].
Our findings also contrast with the short-term effects of olanzapine, which at 100 µM inhibited
isoprenaline-induced lipolysis in rat adipocytes, whereas risperidone was inefficient at the same
dose [11]. Moreover, these observations are in line with the very recent findings of Sarsenbayeva et al.,
who reported during the completion of our work that olanzapine can lower basal lipolysis after
short-term incubation (30 min) with human adipocytes, but not after longer treatment (24 h) [37].
Therefore, the fattening side-effect of olanzapine found in psychotic patients under prolonged treatment
(Zyprexa® at >15 mg/day) did not appear to be mediated by an immediate modulation of lipolytic
activity in adipocytes. This does not mean that the effects of the drug are only central, as olanzapine
can up-regulate or down-regulate gene expression of various key enzymes involved in the regulation
of triglyceride synthesis/breakdown [10].
It was then verified whether these antipsychotics hamper the antilipolytic action of insulin.
Unfortunately, the insulin sensitivity of human adipocyte preparations exhibited high inter-individual
variability and signs of insulin resistance—100 nM of the pancreatic hormone tended to inhibit the
10 nM isoprenaline-induced lipolysis by only 21.3 ± 12.0% (n = 9; NS). Nevertheless, this percentage
of inhibition (antilipolytic effect) raised to 23.6 ± 9.8%, 24.8 ± 12.2%, 39.0 ± 15.1%, and 44.7 ± 11.5%
with 100 µM of olanzapine, ziprazidone, haloperidol, and risperidone, respectively (n = 9; NS). Thus,
no dramatic alteration of insulin responsiveness was observed immediately after the application
of antipsychotic drugs, at least when considering the blunted antilipolytic responses of overweight
individuals. This was in agreement with the lack of change of the adipocyte insulin responsiveness
of rats after prolonged administration of atypical antipsychotic drugs [10], and with the limited
improvement of insulin antilipolytic effect during short-term treatments of rat adipocytes [10,11].
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3.2. Influence of Opipramol on Basal and Stimulated Lipolytic Activity of Human Adipose Cells
We extended a similar approach to the atypical anxiolytic and antidepressant drugs opipramol
(Ensidon) and phenelzine (Nardil) by performing lipolysis assays on other sets of adipocyte preparations.
Our working hypothesis was that opipramol, which is an iminostilbene derivative, would not exhibit
any deleterious effect on lipolysis because it is not recognized for causing weight gain in patients [23],
and that phenelzine could be potentially lipolytic because we recently reported that this MAO
inhibitor limits fat accumulation in rodents [8,9,25], a finding observed with selegiline, another MAO
inhibitor [26].
A serendipitous observation was that opipramol dramatically inhibited isoprenaline activation of
lipolysis in human adipocytes. The sigmoid dose–response to the β-adrenergic agonist (characterized
by an IC50 of 3.3 ± 1.9 nM) was flattened in the presence of 100 µM opipramol (Figure 2).
Figure 2. Impairment by opipramol of isoprenaline lipolytic activation in human subcutaneous
adipocytes. Isoprenaline was tested alone at increasing concentrations (iso alone, black circles, control)
or in the presence of 100 µM opipramol (red squares). Spontaneous glycerol release from freshly
isolated adipocytes (basal) was also tested without and with opipramol. Each point is the mean ± SEM
of 8–9 determinations. Different from the corresponding control at *: p < 0.05; **: p < 0.01; ***: p < 0.001.
Opipramol is known to bind with high affinity to sigma receptors and to a lesser extent to dopamine
receptors [38], but its putative affinity for β-adrenergic receptors is poorly documented. We tested
whether such an unexpected antilipolytic effect of opipramol was also observed when lipolysis is
activated by lipolytic agents other than isoprenaline, in order to discard a putative antagonism at
β-adrenergic receptors. Figure 3 shows that increasing doses of opipramol impaired the lipolytic effect
of forskolin (a direct activator of cAMP generation by adenylyl-cyclase), and the cGMP-dependent
stimulatory effect of ANP as well. Figure 3 also shows that the inhibition of the submaximal activation
of lipolysis by 10 nM isoprenaline was clearly dose-dependent for opipramol between 1 and 100 µM
(the IC50 values ranged around 7 µM).
However, in our conditions, the dose of 1.0 µM opipramol was too low to produce a clear-cut
antilipolytic action, irrespective of the lipolytic agent used to activate triglyceride breakdown.
Because the therapeutic plasma levels of this anxiolytic drug are estimated as being around 0.1 µM,
the antilipolytic effects of opipramol are relevant only in case of overdose or if the drug is accumulated
in adipose tissue [39]. This might explain why opiramole administration is not considered to induce
weight gain in anxious patients. Nonetheless, our experiments indicated that, despite impairing the
stimulation by various lipolytic agents, opipramol was not able to lower the baseline of glycerol release
(see Figure 2).
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Figure 3. Opipramol exhibited inhibitory effect on various lipolytic agents in human abdominal
adipocytes. The lipolytic responses to 10 µM forskolin, 1 µM atrial natriuretic peptide (ANP), or 10 nM
isoprenaline were expressed as percentage of the maximal glycerol release capacity (which reached
0.9 ± 0.1 µmol glycerol/100 mg lipid/90 min in response to 10 µM isoprenaline). Each of these responses
with lipolytic agent alone (control) was impaired by increasing doses of opipramol (from 1 to 100 µM).
Each point is the mean ± SEM of six different adipocyte preparations. Difference between 100 µM
opipramol and its corresponding control with each lipolytic agent alone at **: p < 0.01.
Indeed, testing the putative antilipolytic properties of any given agent in basal conditions is poorly
relevant. This may explain some of the discrepancies found in the literature regarding the effects
of antipsychotic and antidepressant drugs on basal lipolysis [10,11,37]. To further characterize any
antilipolytic capacity, it is more discerning to work under prestimulated conditions. This was therefore
performed by testing how the antilipolytic effect of opipramol could be improved or impaired by
other known antilipolytic agents, such as insulin or tyramine, on isoprenaline submaximal stimulation.
As opipramol augments the therapeutic action of neuroleptics, it was also tested as to whether its
antilipolytic effect was modulated by haloperidol, whereas our study also included the combination
with other inhibitors.
Again, insulin did not significantly inhibit isoprenaline-stimulated lipolysis in this second set of
experiments, that is, when tested at 100 nM against equivalent dose of isoprenaline (Figure 4). This is
not so inconsistent, as human adipocytes are recognized as being less insulin-sensitive than rodent fat
cells, especially in the case of overweight individuals [40]. Nevertheless, the presence of opipramol did
not alter the antilipolytic effect of insulin—there was neither worsening nor addition of their effects
when the two agents were tested simultaneously. In contrast, millimolar concentration of tyramine was
remarkably antilipolytic in human adipocytes, as previously reported [31], and its effect was added to
that of opipramol when combined, leading to an almost complete blockade of isoprenaline lipolytic
stimulation (Figure 4). The α2-adrenergic antagonist RX 821002 (also known as methoxy-idazoxan),
already reported to inhibit the antilipolytic action of α2-agonists in human adipocytes [31], was unable
to counteract the opipramol effect. Haloperidol did not hamper isoprenaline stimulation, in accordance
with its poor effect on weight gain in treated patients [4], and with its above-reported lack of effect on
lipolysis (see Figure 1), and it did not alter opipramol antilipolysis (Figure 4). Lastly, the opipramol
antilipolytic effect also remained unchanged in the presence of the nitic oxide synthase inhibitors
aminoguanidine and L-NAME (Ngamma-nitro-L-arginine methyl ester) (not shown). From these
observations, a putative contribution ofα2-adrenergic component in the antilipolytic effect of opipramol
could be discarded, as well as any interaction with β-adrenergic receptors.
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Figure 4. Combination of opipramol with insulin, tyramine, RX 821002, or haloperidol on
isoprenaline-induced lipolysis in human adipocytes. Human subcutaneous fat cells were incubated for
90 min with 0.1 µM isoprenaline (iso) alone or in combination with the following agents: 0.1 µM insulin,
1 mM, tyramine, 10 µM RX 821002, 100 µM haloperidol. Results are expressed as percentage of 0.1 µM
isoprenaline-induced glycerol release, which averaged 0.91 ± 0.11 µmol glycerol/100 mg lipid/90 min
(n = 6). In parallel, adipocyte suspensions were also incubated in the presence of 100 µM opipramol.
Mean ± SEM of six cases. The lipolysis was significantly lower in the presence of opipramol (open
columns) than in respective control (control, black columns) at **: p < 0.01, ***: p < 0.001. Tyramine
inhibited isoprenaline stimulation at ##: p < 0.01, whereas other agents were inefficient.
Regarding the effect of opipramol on its own on basal lipolysis, a lack of effect was evident from
1 to 100 µM (e.g., 0.18 ± 0.06 vs. 0.19 ± 0.06 µmol glycerol released/100 mg lipid/90 min for 10 µM
opipramol and basal, respectively, n = 6; NS). In all, it could be definitively assessed that opipramol was
not lipolytic, but the exact mechanism of action of its antilipolytic capacity, unmasked in prestimulated
situations, could not be determined.
Because tyramine, a MAO substrate in human adipocytes [24,31], exhibited an effect additive to
that of opipramol, it was necessary to verify whether the latter was interacting with MAO. Before
such verification, we investigated the phenelzine short-term effects on lipolysis, as phenelzine is a
well-recognized MAO inhibitor exhibiting both central effects [41] and direct negative control of lipid
accumulation in adipocytes [6,7].
3.3. Influence of Phenelzine and Pargyline on Basal and Stimulated Lipolytic Activity of Human Adipose Cells
Because phenelzine mitigates excessive fat deposition in mice fed a high-fat diet [8,9], and directly
impairs adipogenesis in cultured preadipocytes [7], we presumed that it could directly favor triglyceride
breakdown in adipose cells.
When tested in similar conditions as above, phenelzine did not acutely alter the effect of
isoprenaline. The maximal effect of 10 µM isoprenaline, set at 100%, was unaltered by the MAO
inhibitor, as in the presence of 1 mM phenelzine it remained 85 ± 10% of the lipolytic stimulation
(n = 7; NS). The historical antidepressant pargyline, another reference of MAO inhibitor, was also
inactive at 1 mM (85 ± 6%; n = 7; NS). In addition, even when tested alone at low or high doses,
phenelzine and pargyline were devoid of notable influence on basal lipolysis, representing at 1 mM
16 ± 10% and 10 ± 18% of maximal effect reached with 10 µM isoprenaline (n = 7; NS).
Considering that phenelzine and pargyline are known as MAO inhibitors, and that norepinephrine
and epinephrine are MAO substrates whereas isoprenaline is not, we further tested both antidepressant
drugs on (nor)epinephrine-stimulated lipolysis. The norepinephrine dose–response exhibited a classical
sigmoid shape that was not altered by the MAO inhibitors (Figure 5, left panel). Although rather
surprising, this finding seems to indicate that MAO inhibitors did not act as protective agents for
norepinephrine, which is readily oxidized by MAO essentially at supra-micromolar doses. Indeed,
at 1 µM, norepinephrine already reached its maximal activation of lipolysis, and any protection from
its degradation cannot further enhance the amplitude of the maximal plateau, observed between 1 and
100 µM.
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Figure 5. Lack of influence of monoamine oxidase (MAO) inhibitors pargyline and phenelzine on the
norepinephrine and epinephrine effects on lipolysis in human subcutaneous adipocytes. Left panel:
dose–response curves of glycerol release were obtained with norepinephrine alone (control, open
circles) or in the presence of pargyline (squares) or phenelzine (triangles) at 1 mM. Mean ± SEM of three
adipocyte preparations. No significant difference between control and 1 mM inhibitor. Right panel:
biphasic action of epinephrine in the presence of propranolol and adenosine deaminase (ADA) in
order to unmask the α2-adrenergic antilipolytic component of the catecholamine (control, open circles).
Mean ± SEM of seven adipocyte preparations. No significant difference between control and 1 mM
pargyline (squares) or phenelzine (triangles).
However, we hypothesized that catecholamine protection against MAO oxidation could be
beneficial not only for the β-adrenergic lipolytic component, but also for the α2-adrenergic antilipolytic
effect of (nor)epinephrine, as both β- and α-adrenoceptors bind these molecules. This was tested
by determining the epinephrine-dependent inhibition of a mild lipolytic activation by adenosine
deaminase (ADA) in the presence of the β-adrenoceptor antagonist propranolol. Effectively, under such
β-blockade, epinephrine impaired the lipolytic effect of ADA, at least between 0.01 and 10 µM, as at 100
µM the β-adrenergic lipolytic component competed for β-adrenergic blockade by 10 µM propranolol
and tended to re-increase glycerol release, resulting in a “U-shaped” curve (Figure 5, right panel). Again,
both α2- and β-adrenergic components were unaltered in the presence of phenelzine or pargyline.
Another experiment aimed to verify whether pargyline or phenelzine could influence the lipolysis
modulation by norepinephrine. It consisted in the addition of 10 µM RX 821002 to norepinephrine
increasing doses, without and with MAO inhibitors. As expected, the blockade of the α2-adrenergic
antilipolytic component of norepinephrine by RX 821002 enhanced its lipolytic effect, resulting from
a predominant β-lipolytic pathway in the α2/β balance (Figure 6, left panel). Such observation was
confirmatory of previous findings [42]. However, phenelzine did not further enhance the lipolytic action
of norepinephrine, even when its α2-component was blocked (Figure 6, right panel). Unexpectedly,
pargyline at a millimolar dose exhibited a tendency to partially blunt the potentiation of norepinephrine
by RX 821002. None of these observations indicated that the MAO inhibitors could be qualified as
lipolytic or pro-lipolytic agents. Obviously, they did not exhibit the noticeable antilipolytic effect
observed with opipramol. Although the antidepressant phenelzine is recognized as inducing some
weight gain in patients, this effect is of lower amplitude than with other antidepressants [41], and this
is not supported by any higher activating influence on lipid mobilization when compared to the
antipsychotics tested here. Because phenelzine has been reported to modestly limit fat accretion in
animal models [8,9,25], this might rather be related to an impairment of lipogenic activity, as reported
in mouse fat cells [6].
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Figure 6. Influence of the MAO inhibitors pargyline and phenelzine on the potentiation of
norepinephrine-induced lipolysis by α2-adrenergic blockade. Left panel: dose–response curves
of glycerol release were obtained with norepinephrine alone (control, open circles) or in the presence
of RX 821002 (NOR+RX, closed circles). Results are expressed as percentage of maximal response to
NOR+RX. Mean ± SEM of 12 adipocyte preparations. Different from respective NOR+RX at *: p < 0.05;
**: p < 0.01. Right panel: Influence of phenelzine (triangles) pargyline (squares) at 1 mM on the RX
821002-induced potentiation of norepinephrine lipolytic activation. Mean ± SEM of six cases. Different
from NOR+RX at **: p < 0.01.
Because opipramol behaved differently from various other psychoactive substances, at least
regarding lipolysis regulation in fat cells, we examined the way in which it interacted with MAO activity
and another major amine oxidase expressed in adipose tissue—the semicarbazide-sensitive amine
oxidase (SSAO) [43]. To this aim, putative interaction with MAO was determined on [14C]-tyramine
oxidation by human adipose tissue homogenates, whereas the interaction with SSAO was tested by
inhibition of [14C]-benzylamine oxidation.
3.4. Interactions of Opipramol and Other Psychotropes with Adipose Tissue Amine Oxidase
To describe the interaction of opipramol and other psychoactive substances with peripheral MAO,
we compared their capacity to inhibit the oxidation of 0.5 mM [14C]-tyramine by human adipose
tissue homogenates (Figure 7, left panel). In parallel, competition experiments were performed with
0.5 mM [14C]-benzylamine (Figure 7, right panel), a SSAO substrate that produces H2O2 once oxidized,
and this activates glucose uptake into human fat cells [27].
As expected, the MAO inhibitors pargyline and phenelzine totally abolished tyramine oxidation
while semicarbazide was inactive, even at 1 mM. Notably, opipramol dose-dependently inhibited
MAO activity with an IC50 that was higher than that of harmine, a MAO-A inhibitor of reference [44].
Risperidone also impaired tyramine oxidation, without reaching complete inhibition at 10 mM. Tested at
a high dose only, the antipsychotics either typical (haloperidol) or atypical (olazanpine, ziprazidone)
were totally unable to hamper MAO activity.
[14C]-Benzylamine oxidation was totally abolished by the reference SSAO inhibitor semicarbazide,
whereas the MAO selective inhibitor pargyline was inefficient, as it was the case of the antipsychotics at
supra-therapeutic dose. Opipramol slightly limited SSAO activity at 1–10 mM. The strongest inhibitor
was phenelzine, which totally blocked SSAO activity, as did semicarbazide (respective IC50 were
0.6 ± 0.2 µM and 80 ± 12 µM) (Figure 7). This is in agreement with the novel nomenclature of SSAO,
renamed PrAO, for primary amine oxidase [45], as the enzyme cannot be named further on the basis of
its sensitivity to its historical inhibitor semicarbazide, which is currently overpassed by other molecules
being more selective and potent (listed in [28]). Nevertheless, it seems that it is the first time that such
an impressive capacity of phenelzine in inhibiting human SSAO is reported for a native, tissue-bound
form (neither recombinant nor purified).
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Figure 7. Influence of typical antipsychotics (haloperidol), atypical antipsychotics (olanzapine, ziprazidone,
risperidone), MAO inhibitor antidepressants (phenelzine, pargyline), tricyclic antidepressants
(opipramol), and various inhibitors (harmine, semicarbazide) on [14C]-tyramine and [14C]-benzylamine
oxidation by human white adipose tissue. Homogenates (approximately 100 µg protein/100 µL) were
preincubated for 15 min with the indicted agents, then incubated for 30 min in the presence of 0.5 mM
[14C]-tyramine (left panel) or 0.5 mM [14C]-benzylamine (right panel). For each amine, results are
expressed as respective oxidation without added agent (100%). Each point is mean ± SEM of four to
nine observations.
Figure 7 also shows a greater inhibition of the oxidation of tyramine than benzylamine by
harmine, an historical inhibitor of MAO, able to limit the degradation of tyramine, serotonin [46],
and kynuramine [44], that is, having more selectivity for MAO-A than for MAO-B (in accordance with
the preponderant MAO-A on MAO-B in human WAT ([24]). Hence, this is the first time, at least to our
knowledge, that data evidence the selectivity of harmine towards MAO relative to SSAO inhibition,
as this β-carboline was inhibiting the production of neosynthesized radiolabeled benzaldehyde up
to 50% only in the millimolar range whereas it deeply inhibited tyramine oxidation at 100 nM. Thus,
already described as binding to MAO [44] and to imidazoline I2-sites [47], harmine is also able to
interact with SSAO to a lesser extent, which is not so astonishing because I2-sites have been described
on SSAO [48,49].
As noted above, the oxidation of amine substrates generates hydrogen peroxide, irrespective of
the amine oxidase catalyzing the oxidative deamination. It was of interest to study the influence of
opipramol and of antipsychotics on the fate of H2O2 in human adipose tissue because the adverse
effects of the latter have been reported to be mitigated by antioxidants [50] or AMP-activated protein
kinase (AMPK) activators [51].
3.5. Opipramol Interacted with Hydrogen Peroxide Generation by Amine Oxidases
Accordingly with the observations made on [14C]-tyramine oxidation, opipramol inhibited MAO
activity in hScAT—the fluorometric determination of H2O2 released during amine oxidation indicated
that the anxiolytic agent reached the same level of inhibition as pargyline (Figure 8A). By contrast,
only supra-therapeutical, millimolar doses of haloperidol inhibited tyramine oxidation, without
exceeding 20% inhibition. Such apparent controversy did not appear when considering their capacities
to impair benzylamine-induced H2O2 production. Yet, the two agents were weak SSAO inhibitors,
whereas semicarbazide was as inhibitory as it was with the radiometric method.
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Figure 8. Dose-dependent inhibition by psychoactive agents of the hydrogen peroxide release by
human adipose tissue homogenates incubated in the presence of tyramine (A) or benzylamine (B).
The positive controls consisted in measuring the production of hydrogen peroxide by homogenates in
the presence of 1 mM of each amine for 30 min, and were set at 100%. Mean ± SEM of seven to eight
observations for tyramine and benzylamine, performed without or with increasing doses of haloperidol
(open circles), opipramol (closed circles), pargyline as a reference MAO inhibitor (shaded triangles,
(A)), and semicarbazide as a reference semicarbazide-sensitive amine oxidase (SSAO) inhibitor (shaded
squares, (B)). In several cases, SEM error bars lie within the symbol.
Several commentaries are needed to further describe these fluorescence-based experiments.
First, phenelzine was not included in the comparative approach, because at doses higher than
10 µM, it generates an autofluorescent signal that impairs hydrogen peroxide detection. This was not
the case for pargyline, haloperidol, opipramol, and semicarbazide—when they were present at 1 mM,
the readouts of fluorescence represented 95 ± 2%, 95 ± 2%, 87 ± 3%, and 105 ± 3% of 5 µM hydrogen
peroxide signal, respectively (n = 6–12).
Second, the H2O2 spontaneous release by human adipose tissue, in the absence of added amine,
averaged 0.21 ± 0.03 nmol/100 mg protein/min and represented 30% of the levels detected in the
presence of tyramine, or 20% of those seen with benzylamine, that is, corresponding to remaining
portions when maximal inhibitions were reached by 1 mM of each reference inhibitor, and by opipramol
in the case of tyramine (Figure 8). Consequently, it did not appear that the tested agents limited
spontaneous hydrogen peroxide release.
Third, the combination of pargyline + semicarbazide (P + S) did not further inhibit the
tyramine-induced signal any more than did the MAO-inhibitor pargyline (28 ± 3% vs. 27 ± 4%, NS). In
addition, P + S inhibited as much as semicarbazide the benzylamine signal (17 ± 2% vs. 20 ± 3%, NS).
This indicated that, alongside baseline H2O2 production, the tyramine-induced signal was mainly
MAO-dependent, whereas the benzylamine signal was predominantly due to SSAO activity.
Fourth, the tendency of 1 mM haloperidol to inhibit hydrogen peroxide release when human
adipose tissue was incubated with either benzylamine or tyramine was not due to its vehicle, DMSO
(1% v/v final) because more than 93% of the fluorescence signal was detected in the presence of 1%
DMSO (not shown). Thus, only a weak tendency to inhibit MAO and SSAO activity can be attributed
to the supra-therapeutic doses of this typical antipsychotic.
Lastly, once all these considerations were taken into account, these experiments described
noticeable MAO inhibitory properties for opipramol, therefore adding more complexity for the
classification of this agent used for the treatment of neuropsychiatric disorders, which does not fit
typically in only one of the following groups: antidepressants, antipsychotics, or anxiolytics.
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3.6. Lack of Opipramol Effect on Basal or Insulin-Induced Glucose Uptake in Human Adipocytes
Besides lipid mobilization, the incorporation of glucose into lipids is a pathway by which
adipocytes manage their size and energy stores. In a search for other direct actions of opipramol on
fat cells, it was tempting to verify whether the pharmaceutical agent could alter glucose transport,
especially its component highly regulated by insulin. The human adipocyte preparations used in
these experiments were not tested in parallel, and exhibited different insulin responsiveness regarding
activation of hexose uptake, as in one set, the basal glucose was hardly doubled compared to baseline,
whereas in the other, the maximal response to insulin reached an approximately fourfold increase over
basal uptake (Table 1). Nonetheless, neither opipramol nor phenelzine was able to activate uptake or to
alter insulin stimulation of glucose transport (Table 1). However, phenelzine, owing to its capacity to
abolish SSAO activity, inhibited the glucose transport activation by benzylamine, already documented
to mimic insulin effect in an H2O2-dependent and SSAO-mediated manner [27].
Such observation of a lack of direct interplay between opipramol or phenelzine and glucose
transport is in agreement with previous observations [6], and contrasts with the direct impairment
of insulin signaling reported for olanzapine in muscle cells [52]. Whether the psychoactive drugs
act differently on the glucose transport in adipose depots than in muscles or in other tissues is
highly conceivable, at least regarding to the discrepancies observed rats after chronic treatment with
olanzapine treatment—induction of insulin resistance without alteration of insulin stimulation of
glucose transport in adipocytes [10].
Table 1. Glucose transport in human adipocytes.
Hexose Uptake into Fat Cells (Fold Increase of Basal 2-DG Uptake)
Experiment 1 Experiment 2
Control +Opipramol Control +Phenelzine
basal 1.00 ± 0.16 1.12 ± 0.14 1.00 ± 0.15 1.09 ± 0.15
insulin 10 nM 2.05 ± 0.38 * 2.12 ± 0.55 * 3.18 ± 0.42 ** ND
insulin 100 nM 2.66 ± 0.29 ** 2.41 ± 0.47 ** 3.91 ± 0.55 ** 4.09 ± 0.63 **
benzylamine 1 mM ND ND 1.60 ± 0.14 * 1.03 ± 0.20 #
2-Deoxyglucose (2-DG) uptake was assayed on 10 min after 45 min incubation with the indicated agents, in the
absence (control) or in the presence of 100 µM of opipramol (experiment 1) or phenelzine (experiment 2). Values
are means ± SEM of 4 and 10 individuals for experiment 1 and 2, respectively. Different from respective basal at
*: p < 0.05; **: p < 0.01. Different from corresponding control at #: p < 0.05. ND: not determined.
4. Conclusions
Olanzapine, which is an antipsychotic well-recognized for its adverse effects on weight gain and
glucose homeostasis, was not the worst of the diverse pharmaceutical agents tested on lipolytic activity
of adipocytes. In the present study, this molecule did not acutely impair lipolysis regulation in human
fat cells, although it has been previously demonstrated to alter lipolytic responses after prolonged
treatments in rodents or in cultured preadipocytes [11,12,15]. Besides interspecific differences, it seems
that it is the mode of action of olzanzapine that underlies such discrepancies. The drug probably
more dramatically alters the gene regulation of key factors involved in the triglyceride metabolism
(hormone-sensitive lipase, fatty acid synthase) than the short-term regulation of enzyme activities
involved in lipolysis. Facing to this lack of novel insight regarding olanzapine adverse effects, our
study evidenced unexpected properties of other antidepressant drugs, as highlighted below.
Phenelzine is an antidepressant drug considered as a MAO inhibitor, which also inhibits SSAO,
renamed primary amine oxidase or vascular adhesion protein-1 (SSAO/PrAO/VAP-1) [45]. Although
it is associated with a limited body weight gain in treated depressed patients [41], we have recently
reported that it can improve metabolic control and limit fat accretion in mouse models [8,9]. Here, we
report its impressive capacity to inhibit human SSAO at a submicromolar dose. These findings are
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therefore totally confirmatory of a previous report accumulating three independent approaches showing
that phenelzine strongly inhibits SSAO: pharmacological high-throughput screening, enzyme kinetics,
and computational docking [53]. Moreover, the present findings bring evidence that phenelzine direct
action on adipocytes affects the glucose transport dependent on biogenic amine degradation, as well as
its related hydrogen peroxide handling, rather than the lipolytic response to catecholamines. Contrarily
to olanzapine, such a drug is not considered to hamper insulin sensitivity, and this was verified in our
limited model, as it did not alter short-term insulin activation of glucose uptake in fat cells. Initially
considered as only a “protective” agent allowing a longer half-life for catecholamines and facilitating
their postsynaptic actions, this multipurpose molecule still deserves further studies and remains a good
candidate for drug repurposing, as is the case for olanzapine, recently proposed for neurodegenerative
diseases with body weight loss [54]. In this view, its direct antiadipogenic [7] and antilipogenic [6]
actions on adipose cells should be taken into account, as well as its carbonyl scavenger properties and
its interactions with the gamma-aminobutyric acid (GABA)-ergic system [22,55].
We serendipitously observed that opipramol inhibits the lipolytic activation by cAMP-
or cGMP-dependent pathways. Among the diverse psychoactive drugs tested in this study,
only risperidone partially reproduced such an antilipolytic effect. Surprisingly, opipramol treatment
is not associated with adverse body weight gain, as is the case for olanzapine. One can assert that
the in vitro effects of these drugs are not predictive of their therapeutic actions because they were
mainly observed at supra-therapeutic levels. However, opipramol is administered at doses up to
200 mg/day [23,38], making our observations at 1–10 µM relevant. Moreover, risperidone, which
induces a modest antilipolytic effect, also modestly increases adiponectin levels in treated patients
with schizophrenia, wheraes olanzapine decreases the circulating levels of this insulin-sensitizing
adipokine [56] and increases pro-inflammatory cytokines [57]. This allows the supposition that
opipramol could also have opposite effects to olanzapine when considering adipocyte functions other
than lipolysis and glucose transport. Thus, lipogenic responses and adipokine secretion deserve to be
further studied with opipramol. Evidently, other central and peripheral actions of these pharmacological
agents may entirely explain their different influence on adipose tissue development. In this view,
it can be hypothesized than the antilipolytic properties of opipramol might be accompanied by a
protective action towards the onset of insulin resistance. As proposed for other antilipolytic agents [58],
such potential benefits may occur by limiting the deleterious consequences of excessive circulating
lipids, also known as lipotoxicity, which contributes to the complications of various metabolic diseases.
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